ICON launches FIRECREST Financial Disclosure to Reduce Administrative Costs and Increase Regulatory Compliance
May 21 2018 - 7:00AM
Business Wire
ICON plc, (NASDAQ: ICLR) a global provider of drug development
and commercialisation solutions and services, today announced the
launch of FIRECREST Financial Disclosure, an innovative digital
solution that increases the efficiency and compliance of
investigator Financial Disclosure administration. FIRECREST
Financial Disclosure provides a robust solution for sponsors to
distribute, track and manage the completion of forms mandated by
FDA 21CFR Part 54 (Financial Disclosure by Clinical Investigators).
The solution enables secure, centralised, electronic distribution
and response capture of Financial Disclosure information.
ICON has developed FIRECREST Financial Disclosure to address the
ongoing industry challenge of non-compliance due to incomplete
forms and to ensure necessary regulatory requirements are in place
in advance of study start-up. The solution reduces the risk of
regulatory findings and reduces administrative costs associated
with traditional distribution and tracking of form completion.
“FIRECREST Financial Disclosure supports sponsors to increase
compliance and manage the Financial Disclosure process more
efficiently.” commented Mark Connolly, VP FIRECREST at ICON. “We
estimate the solution is capable of delivering savings in excess of
50% when compared to traditional methods, while also contributing
to the environmental sustainability targets of our clients”.
Financial Disclosure is the latest addition to the FIRECREST
digital solutions suite, developed to increase efficiency in
clinical trials by driving site performance. Solutions include
award winning GCP and Protocol Training Animations, Visit By Visit
Guide, Trial Drive and Pre-Screen. To learn more about FIRECREST,
visit www.iconplc.com/FIRECREST.
About ICON plc
ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to pharmaceutical,
biotechnology, medical device, and government and public health
organisations. The company specializes in the strategic
development, management and analysis of programs that support
clinical development from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 97 locations in 38 countries and has approximately
13,380 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180521005491/en/
ICON Media ContactOlivia PimentaWeber Shandwick44-207 067
0557OPimenta@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2024 to May 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From May 2023 to May 2024